[Robert: paste actual Google Review quote — filtered to mention this page's topic]
[Robert: First name + initial]
[Robert: month year of review]
Triple-pathway agonist combining GLP-1, GIP, and Glucagon receptors. The latest generation of weight-loss medicine — clinical research demonstrates the strongest outcomes to date. Available exclusively through private consultation with your supervising physician.
Peptides like Retatrutide require strict 2–8°C cold-chain maintenance throughout the entire supply chain. Where our Investigational Therapy Program operates, source quality matters more than distance traveled.
Peptide stability is sensitive to temperature deviations. Intercontinental shipping (typically 18–72 hours flight + customs + last-mile delivery) introduces multiple cold-chain transition points. Our Bangkok-based supply route reduces these transitions significantly — direct pharmacy-to-clinic workflow under continuous 2–8°C protocol.
Our Investigational Therapy Program partners with an Asia-leading licenced and accredited compounding pharmacy in Bangkok (10+ years of service to hospitals and clinics across the region). Raw materials are verified via HPLC (High-Performance Liquid Chromatography) and mass spectrometry to confirm potency and authenticity prior to dispense.
Our supply partner operates under Good Manufacturing Practice (GMP) protocols and internationally recognized ISO-quality standards. All products maintain documentation trail from raw-material lot through dispense — supporting your doctor's review process and your peace of mind.
Before any decision, our supervising physician reviews your current prescriptions, medical background, and individual eligibility — ensuring any considered treatment fits your overall health context. No standardized "one-size-fits-all" approach. Personalized, evidence-based, conservative.
All claims subject to current Thai medical regulations · individual eligibility · physician's discretion. References available on request.
That's −20.6 kg — you'd weigh .
Based on the 24.2% trial-mean. Individual outcomes vary.
Licensed medical facility · Real photos
Retatrutide is the first investigational medicine to activate three different gut-derived hormone receptors simultaneously — GLP-1, GIP, and Glucagon. Where Tirzepatide engages two receptors and Semaglutide engages one, the triple-agonist design adds glucagon-receptor stimulation, which increases energy expenditure on top of appetite suppression. In the Phase 2 obesity trial, patients on the highest dose demonstrated mean body-weight reduction of 24.2% over 48 weeks[1] — the strongest published outcome among incretin-class medicines to date. Phase 3 trials in the TRIUMPH program are ongoing[3].
Slows gastric emptying, suppresses appetite, improves insulin response. The foundational pathway shared with Semaglutide and Tirzepatide.
Improves fat metabolism and insulin sensitivity. Shared with Tirzepatide — but in Retatrutide, layered with the third receptor for greater combined effect.
The unique addition. Glucagon-receptor activation increases basal energy expenditure — the body burns more calories at rest, on top of eating less. This third lever differentiates Retatrutide from all approved alternatives.
For the broader weight-loss medicine landscape including FDA-approved alternatives, see our Weight Loss Thailand overview or the Tirzepatide and Semaglutide pages.
Three weekly injectable medicines, each at a different stage of receptor engagement and regulatory status.
| Dimension | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Average weight loss | 15-17% (STEP-1) | 20-22% (SURMOUNT-1) | 24%+ (TRIUMPH Phase 3) |
| Receptor pathways | GLP-1 | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
| Status | Approved · Wegovy & Ozempic | Approved · Mounjaro & Zepbound | Phase 3 complete · approval anticipated |
| Dosing | Weekly subcutaneous | Weekly subcutaneous | Weekly subcutaneous |
| Common brand | Wegovy, Ozempic | Mounjaro, Zepbound | No commercial brand yet |
| Best fit for | First-time GLP-1 patients | Patients seeking stronger efficacy than GLP-1 alone | Highest BMI, prior GLP-1 plateau, latest research |
Your supervising physician reviews your medical history, BMI, prior treatment, and goals during the private consultation to discuss which option fits best.
Retatrutide is the world's first Triple-G Pathway agonist — targeting GLP-1 (appetite/digestion), GIP (fat/sugar metabolism) and Glucagon (energy expenditure). In TRIUMPH Phase 2 trials, mean body-weight reduction reached 24.2% at 48 weeks (highest dose) — the highest documented for any weight-loss molecule in this timeframe. Phase 3 trials (TRIPHASE program) are ongoing worldwide · expected FDA-approval window 2025–2026. Our Investigational Therapy Program educates eligible patients about Retatrutide while supporting your current best-fit treatment (Mounjaro, Wegovy, Tirzepatide).
Book a consultation through our Investigational Therapy Program to (1) discuss your current best-fit GLP-1 treatment today, (2) get an educational review of Retatrutide's trial data and timeline, and (3) be among the first informed when approval reaches your jurisdiction.
Get pricing on WhatsApp →Educational reference based on the TRIUMPH Phase 2 clinical-trial mean. Retatrutide is investigational (Phase 3) — this chart shows trial-population averages only. Currently available alternatives (Mounjaro, Wegovy) discussed in consultation.
Your trajectory · based on TRIUMPH Phase 2 mean (Retatrutide)
Estimator uses peer-reviewed clinical-trial mean data. Individual outcomes vary based on adherence, baseline BMI, comorbidities, and lifestyle factors. Final program plan determined in private medical consultation.[ref]
Retatrutide follows a 4-step titration protocol matched to the TRIUMPH trial design — 4 weeks at each dose level to allow GI adaptation before stepping up.
Source: TRIUMPH Phase 3 program titration design. Adapted individually based on tolerance and response by your supervising physician.
15-minute WhatsApp with our supervising physician. Share your goals, history, and questions. No commitment.
A specialist physician reviews your history. Labs ordered if needed. Treatment plan decided based on your specific clinical picture.
First dose at clinic or cold-chain delivery to your address. Titration plan + side-effect support from day one.
Weekly check-ins during titration. Dose adjusted to your response. Sustainable maintenance plan together.
Every Retatrutide patient is personally supervised by an endocrine specialist — medical history review, HbA1c monitoring where relevant, dose decisions, titration adjustments. No intake-form-only approval.
Authentic pharmaceutical-grade Retatrutide via licensed cold-chain pharmacy distribution. Sealed vials with batch numbers and expiry dates intact. No compounded substitutes, no grey-market sourcing.
In-clinic in Pattaya, concierge nurse to your hotel in Bangkok, or online consultation with cold-chain delivery in Phuket and beyond.
Real reviews from real patients on Google Business Profile. Currently 5.0 ★ from 15 verified reviews — and growing. Updating list is syncing automatically (Phase 2 integration).
[Robert: paste actual Google Review quote — filtered to mention this page's topic]
[Robert: paste actual Google Review quote — filtered to mention this page's topic]
[Robert: paste actual Google Review quote — filtered to mention this page's topic]
Retatrutide access is information-confidential. Your supervising physician responds within minutes on WhatsApp and walks you through eligibility, protocol, sourcing, and the program structure that fits your situation.
Request consultationPeer-reviewed primary sources and clinical-trial registries.
Additional clinical questions are discussed during your private consultation with your supervising physician.
Each GLP-1 protocol has a different mechanism, trial profile, and outcome ceiling. Compare or explore by location.
Side-by-side comparison of all GLP-1 programs with outcome estimator and cost.
See program →
Dual GIP/GLP-1 receptor agonist. Highest trial-mean of any approved GLP-1 medicine.
See program →
Most-prescribed GLP-1 in clinical practice. Excellent track record for goals up to 15%.
See program →
In-person consultation, baseline labs, same-week start. Walk-in friendly.
See program →